drugset / Trial / NCT05030025
Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)
RandomizedCrossoverOpen-labelTreatment
Summary
The rationale for this study is to evaluate and understand the variability of a generic alternative of abacavir, dolutegravir and lamivudine dispersible tablets for PEPFAR submission to aide in the development of pivotal studies.
Timeline
- Start
- 2021-08-01
- Primary completion
- 2021-08-29
- Completion
- 2021-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abacavir | Other / unclassified | 60 mg | Oral |
| Subject | Dolutegravir | Other / unclassified | 5 mg | Oral |
| Subject | Lamivudine | Other / unclassified | 30 mg | Oral |